Saudi guidelines on the diagnosis and treatment of pulmonary hypertension

Pulmonary arterial hypertension associated with connective tissue diseases

Adel Boueiz, Paul M Hassoun

Research output: Contribution to journalArticle

Abstract

The explosive growth of medical literature on pulmonary hypertension (PH) has led to a steady increase in awareness of this disease within the medical community during the past decade. The recent revision of the classification of PH is presented in in the main guidelines. Group 1 PH or pulmonary arterial hypertension (PAH) is a heterogeneous group and includes PH due to inheritable, drug-induced, and toxin-induced causes and to such underlying systemic causes as connective tissue diseases, human immunodeficiency viral infection, portal hypertension, congenital heart disease, and schistosomiasis. Systemic sclerosis (SSc) is an autoimmune multisystem disorder, which affects over 240 persons per million in the United States. [1] Its manifestations are not confined to the skin but may also involve the lungs, kidneys, peripheral circulation, musculoskeletal system, gastrointestinal tract, and heart. The outcome of PAH associated with SSc is worse when compared to other subtypes of PAH. In this review, we summarize available information about the pulmonary vascular and cardiac manifestations of SSc with special emphasis on their prognostic implications as well as the peculiarity of their detection.

Original languageEnglish (US)
JournalAnnals of Thoracic Medicine
Volume9
Issue numberSUPPL. 1
DOIs
StatePublished - 2014

Fingerprint

Connective Tissue Diseases
Pulmonary Hypertension
Guidelines
Systemic Scleroderma
Musculoskeletal System
Lung
Renal Circulation
Schistosomiasis
Portal Hypertension
Virus Diseases
Blood Vessels
Gastrointestinal Tract
Heart Diseases
Skin
Growth
Pharmaceutical Preparations

Keywords

  • connective tissue disease
  • Pulmonary arterial hypertension
  • right ventricular failure
  • Saudi association for pulmonary hypertension guidelines
  • systemic sclerosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

@article{e2954e5b4cf342cbbbc8fc3140faaf60,
title = "Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: Pulmonary arterial hypertension associated with connective tissue diseases",
abstract = "The explosive growth of medical literature on pulmonary hypertension (PH) has led to a steady increase in awareness of this disease within the medical community during the past decade. The recent revision of the classification of PH is presented in in the main guidelines. Group 1 PH or pulmonary arterial hypertension (PAH) is a heterogeneous group and includes PH due to inheritable, drug-induced, and toxin-induced causes and to such underlying systemic causes as connective tissue diseases, human immunodeficiency viral infection, portal hypertension, congenital heart disease, and schistosomiasis. Systemic sclerosis (SSc) is an autoimmune multisystem disorder, which affects over 240 persons per million in the United States. [1] Its manifestations are not confined to the skin but may also involve the lungs, kidneys, peripheral circulation, musculoskeletal system, gastrointestinal tract, and heart. The outcome of PAH associated with SSc is worse when compared to other subtypes of PAH. In this review, we summarize available information about the pulmonary vascular and cardiac manifestations of SSc with special emphasis on their prognostic implications as well as the peculiarity of their detection.",
keywords = "connective tissue disease, Pulmonary arterial hypertension, right ventricular failure, Saudi association for pulmonary hypertension guidelines, systemic sclerosis",
author = "Adel Boueiz and Hassoun, {Paul M}",
year = "2014",
doi = "10.4103/1817-1737.134016",
language = "English (US)",
volume = "9",
journal = "Annals of Thoracic Medicine",
issn = "1817-1737",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Saudi guidelines on the diagnosis and treatment of pulmonary hypertension

T2 - Pulmonary arterial hypertension associated with connective tissue diseases

AU - Boueiz, Adel

AU - Hassoun, Paul M

PY - 2014

Y1 - 2014

N2 - The explosive growth of medical literature on pulmonary hypertension (PH) has led to a steady increase in awareness of this disease within the medical community during the past decade. The recent revision of the classification of PH is presented in in the main guidelines. Group 1 PH or pulmonary arterial hypertension (PAH) is a heterogeneous group and includes PH due to inheritable, drug-induced, and toxin-induced causes and to such underlying systemic causes as connective tissue diseases, human immunodeficiency viral infection, portal hypertension, congenital heart disease, and schistosomiasis. Systemic sclerosis (SSc) is an autoimmune multisystem disorder, which affects over 240 persons per million in the United States. [1] Its manifestations are not confined to the skin but may also involve the lungs, kidneys, peripheral circulation, musculoskeletal system, gastrointestinal tract, and heart. The outcome of PAH associated with SSc is worse when compared to other subtypes of PAH. In this review, we summarize available information about the pulmonary vascular and cardiac manifestations of SSc with special emphasis on their prognostic implications as well as the peculiarity of their detection.

AB - The explosive growth of medical literature on pulmonary hypertension (PH) has led to a steady increase in awareness of this disease within the medical community during the past decade. The recent revision of the classification of PH is presented in in the main guidelines. Group 1 PH or pulmonary arterial hypertension (PAH) is a heterogeneous group and includes PH due to inheritable, drug-induced, and toxin-induced causes and to such underlying systemic causes as connective tissue diseases, human immunodeficiency viral infection, portal hypertension, congenital heart disease, and schistosomiasis. Systemic sclerosis (SSc) is an autoimmune multisystem disorder, which affects over 240 persons per million in the United States. [1] Its manifestations are not confined to the skin but may also involve the lungs, kidneys, peripheral circulation, musculoskeletal system, gastrointestinal tract, and heart. The outcome of PAH associated with SSc is worse when compared to other subtypes of PAH. In this review, we summarize available information about the pulmonary vascular and cardiac manifestations of SSc with special emphasis on their prognostic implications as well as the peculiarity of their detection.

KW - connective tissue disease

KW - Pulmonary arterial hypertension

KW - right ventricular failure

KW - Saudi association for pulmonary hypertension guidelines

KW - systemic sclerosis

UR - http://www.scopus.com/inward/record.url?scp=84902489907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902489907&partnerID=8YFLogxK

U2 - 10.4103/1817-1737.134016

DO - 10.4103/1817-1737.134016

M3 - Article

VL - 9

JO - Annals of Thoracic Medicine

JF - Annals of Thoracic Medicine

SN - 1817-1737

IS - SUPPL. 1

ER -